Claims for Patent: 9,186,403

Summary for Patent: 9,186,403

Title:	Compositions including triciribine and trastuzumab and methods of use thereof
Abstract:	This application relates to combination therapies including triciribine and related compounds and trastuzumab or a salt thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
Inventor(s):	Cheng; Jin Q. (Tampa, FL), Sebti; Said M. (Tampa, FL)
Assignee:	University of South Florida (Tampa, FL)
Application Number:	14/091,072
Patent Claims:	1. A method for treating a subject having a tumor or cancer, which tumor or cancer overexpresses AKT kinase comprising: (i) determining whether the subject has a tumor or cancer that overexpresses AKT kinase; (ii) if said subject has a tumor or cancer that overexpresses AKT kinase, a. administering to said subject: i. at least one compound of formula I selected from the group consisting of the following compounds: ##STR00011## wherein each R.sub.2', R.sub.3', and R.sub.5' is independently hydrogen; optionally substituted phosphate or phosphonate; mono-, di-, or triphosphate; acyl; lower acyl; alkyl; lower alkyl; amide; sulfonate ester; alkyl sulfonate ester; arylalkyl sulfonate ester; sulfonyl; methanesulfonyl; benzyl sulfonyl, wherein the phenyl group of said benzyl is optionally substituted with one or more halo, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate; optionally substituted arylsulfonyl; a lipid; phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group that, in vivo, provides a compound of said formula I wherein R.sub.2', R.sub.3' or R.sub.5' is independently H or mono-, di- or tri-phosphate; wherein R.sup.xand R.sup.yare independently hydrogen; optionally substituted phosphate; acyl; lower acyl; amide; alkyl; lower alkyl; aromatic; polyoxyalkylene; polyethyleneglycol; optionally substituted arylsulfonyl; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group; and wherein R.sub.1 and R.sub.2 each are independently H, optionally substituted straight chained, branched or cyclic alkyl, lower alkyl, alkenyl, or alkynyl, CO-alkyl, CO-alkenyl, CO-alkynyl, CO-aryl or heteroaryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonyl, alkysulfonyl, arylsulfonyl, or aralkysulfonyl; ii. trasturzumab or a salt thereof: iii. a pharmaceutically acceptable carrier, wherein the compound of formula I is administered to said subject in an amount of at least 0.5 mg/m.sup.2. 2. The method of claim 1, wherein the compound of formula I is triciribine. 3. The method of claim 1, wherein the compound of formula I is triciribine phosphate. 4. The method of claim 1, wherein the compound of formula I is triciribine phosphonate. 5. The method of claim 1, wherein the compound of formula I is present in a dose amount of at least 20 mg/m.sup.2. 6. The method of claim 1, wherein the compound of formula I is present in an amount of at least 10 mg/m.sup.2. 7. The method of claim 1, wherein the administration is parenteral administration. 8. The method of claim 7, wherein the parenteral administration is intravenous administration. 9. The method of claim 1, wherein the administration is oral administration. 10. The method of claim 1, wherein the trastuzumab or salt thereof is administered in an amount of less than 300 mg. 11. The method of claim 1, wherein the administration of a compound of formula I and the trastuzumab or salt thereof is concurrently administered. 12. The method of claim 1, wherein the administration of a compound of formula I is followed by the administration of the trastuzumab or salt thereof. 13. The method of claim 1, wherein the administration of the trastuzumab or salt thereof is followed by the administration of a compound of formula I.

Details for Patent 9,186,403

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2024-03-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2024-03-29
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2024-03-29